(Q74053057)
Statements
A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer (English)
S H Bernstein
C J Eaves
R Herzig
J Fay
J Lynch
G L Phillips
N Christiansen
D Reece
S Ericson
M Stephan
M Kovalsky
K Hawkins
H Rasmussen
A Devos
1 December 1997